ASMBのチャート
ASMBの企業情報
| symbol | ASMB |
|---|---|
| 会社名 | Assembly Biosciences Inc （アセンブリ―・バイオサイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 アセンブリ・バイオサイエンス(Assembly Biosciences Inc.)はバイオテクノロジー会社である。同社はB型肝炎ウイルス（HBV）感染症の治療向け口腔治療薬及びジビオティックな微生物に健康を回復するように設計された経口合成生治療薬という2つのプラットフォーム・プログラムの開発に従事する。同社はHBVコア（HBc）タンパク質を直接的に標的とし、アロステリックに調節する低分子であるコアタンパク質アロステリックモジュレーター（CpAM）を発見した。マイクロビオムプログラムは、菌株の同定と選択プロセスを含む統合的プラットフォームと菌株の分離と増殖のための方法、下部胃腸（GI）管にライブ生物学的と従来の療法の標的経口送達を可能にする送達システムGEMICELを含む。このプラットフォームの主要製品候補であるAB-M101はクロストリジウム・ディフィシル感染症の治療薬として開発中である。 アセンブリ―・バイオサイエンシズは米国のバイオ医薬品会社。主にB型肝炎ウィルス(HBV)やクロストリジウム・ディフィシル(CDAD)などの感染症疾患の新治療薬の開発・商品化に焦点を当てる。研究開発施設をサンフランシスコ及びニューヨークに置く。本社はニューヨーク。 Assembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio's approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio's strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets. |
| 本社所在地 | 11711 North Meridian Street Suite 310 Carmel IN 46032 USA |
| 代表者氏名 | Derek A. Small デレク・A・スモール |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 212-554-4388 |
| 設立年月日 | 38626 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 79人 |
| url | www.assemblybio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/asmb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -68.11952 |
| 終値（lastsale） | 26.02 |
| 時価総額（marketcap） | 662117383.58 |
| 時価総額 | 時価総額（百万ドル） 643.79590 |
| 売上高 | 売上高（百万ドル） 12.75800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 551.12366 |
| 当期純利益 | 当期純利益（百万ドル） -66.93408 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Assembly Biosciences Inc revenues increased from $3M to $6.8M. Net loss increased 56% to $43.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase from $10.9M to $26.2M (expense) Stock-based Compensation in SGA increase from $1.1M to $9.5M (expense). |
ASMBのテクニカル分析
ASMBのニュース
Assembly Biosciences Inc. (NASDAQ:ASMB) Is Up 40.16% Over The Past 30 Days: Is There Trouble Ahead? 2023/01/28 19:00:00 Marketing Sentinel
In last trading session, Assembly Biosciences Inc. (NASDAQ:ASMB) saw 0.37 million shares changing hands with its beta currently measuring 0.55. Company’s recent per share price level of $1.71 trading at $0.03 or 1.79% at ring of the bell on the day assigns it a market valuation of $84.01M. That closing price of ASMB’s stock is … Assembly Biosciences Inc. (NASDAQ:ASMB) Is Up 40.16% Over The Past 30 Days: Is There Trouble Ahead? Read More »
Assembly Biosciences Inc. (NASDAQ: ASMB) Stocks Rise 18.46% YTD; What Next For It? 2023/01/14 15:00:00 Marketing Sentinel
Assembly Biosciences Inc. (NASDAQ:ASMB)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 0.52. At the close of trading, the stock’s price was $1.54, to imply an increase of 2.67% or $0.04 in intraday trading. The ASMB share’s 52-week high remains $2.42, putting it -57.14% down since that … Assembly Biosciences Inc. (NASDAQ: ASMB) Stocks Rise 18.46% YTD; What Next For It? Read More »
Analyst Predictions On Assembly Biosciences Inc.’s (NASDAQ: ASMB) Future Growth 2022/12/20 13:00:00 Stocks Register
Assembly Biosciences Inc. (NASDAQ:ASMB) price closed higher on Monday, December 19, jumping 14.53% above its previous close. A look at the daily price movement shows that the last close reads $1.17, with intraday deals fluctuated between $1.28 and $1.46. The company’s 5Y monthly beta was ticking 0.72. Taking into account the 52-week price action we … Analyst Predictions On Assembly Biosciences Inc.’s (NASDAQ: ASMB) Future Growth Read More »
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs 2022/12/19 20:19:54 Benzinga
Assembly Biosciences Inc (NASDAQ: ASMB ) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334). For the Phase 1b trial of 3733, the dose selected for the first cohort was 50 mg. A dose of 100 mg has been selected for the third cohort, for which dosing is ongoing, with initial data anticipated in Q1 of 2023. Related:
Assembly Biosciences surges 19% on positive data from two trials to treat HBV 2022/12/19 14:07:50 Seeking Alpha
Assembly Biosciences (ASMB) is trading ~19% higher premarket after it announced positive data from two ongoing studies of its investigational hepatitis B virus (HBV) inhibitors, a Phase…
Analyst Predictions On Assembly Biosciences Inc.’s (NASDAQ: ASMB) Future Growth 2022/12/20 13:00:00 Stocks Register
Assembly Biosciences Inc. (NASDAQ:ASMB) price closed higher on Monday, December 19, jumping 14.53% above its previous close. A look at the daily price movement shows that the last close reads $1.17, with intraday deals fluctuated between $1.28 and $1.46. The company’s 5Y monthly beta was ticking 0.72. Taking into account the 52-week price action we … Analyst Predictions On Assembly Biosciences Inc.’s (NASDAQ: ASMB) Future Growth Read More »
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs 2022/12/19 20:19:54 Benzinga
Assembly Biosciences Inc (NASDAQ: ASMB ) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334). For the Phase 1b trial of 3733, the dose selected for the first cohort was 50 mg. A dose of 100 mg has been selected for the third cohort, for which dosing is ongoing, with initial data anticipated in Q1 of 2023. Related:
Assembly Biosciences surges 19% on positive data from two trials to treat HBV 2022/12/19 14:07:50 Seeking Alpha
Assembly Biosciences (ASMB) is trading ~19% higher premarket after it announced positive data from two ongoing studies of its investigational hepatitis B virus (HBV) inhibitors, a Phase…
Companies - FY2022 Earnings Estimate for Assembly Biosciences, Inc. Issued By HC Wainwright 2022/11/14 07:45:12 Business Mag
Assembly Biosciences, Inc. - Stock analysts at HC Wainwright upped their FY2022 earnings per share estimates for Assembly Biosciences in a research note issued to investors on…
Assembly Biosciences Earnings Miss, Revenue In line In Q3 By Investing.com 2022/11/09 03:52:00 Investing.com
Assembly Biosciences Earnings Miss, Revenue In line In Q3
Companies - FY2022 Earnings Estimate for Assembly Biosciences, Inc. Issued By HC Wainwright 2022/11/14 07:45:12 Business Mag
Assembly Biosciences, Inc. - Stock analysts at HC Wainwright upped their FY2022 earnings per share estimates for Assembly Biosciences in a research note issued to investors on…
Assembly Biosciences Earnings Miss, Revenue In line In Q3 By Investing.com 2022/11/09 03:52:00 Investing.com
Assembly Biosciences Earnings Miss, Revenue In line In Q3
Assembly Biosciences GAAP EPS of -$0.48 beats by $0.06 (NASDAQ:ASMB) 2022/11/08 22:04:48 Seeking Alpha
Assembly Biosciences press release (ASMB): Q3 GAAP EPS of -$0.48 beats by $0.06.Cash, cash equivalents and marketable securities were $108.7 million as of September 30, 2022, compared…
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation 2022/11/08 21:05:00 GlobeNewswire
Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance
Assembly Biosciences Presents New Data at AASLD The Liver Meeting Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV 2022/11/04 12:00:00 Wallstreet:Online
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data presented on preclinical characterization of potent, orally bioavailable viral entry inhibitors for HBV and hepatitis D virus (HDV) First data presented on novel series of orally bioavailable small molecule